Mineralys Therapeutics (MLYS) announced detailed results from the pivotal Phase 3 Launch-HTN trial in over 1,000 participants ...

Mineralys has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Detailed price information for Mineralys Therapeutics Inc (MLYS-Q) from The Globe and Mail including charting and trades.

On Wednesday, 14 May 2025, Mineralys Therapeutics (NASDAQ:MLYS) participated in the BofA Securities 2025 Healthcare Conference, presenting promising developments in its aldosterone synthase inhibitor, ...

Mineralys expects to announce top-line data from the Explore-CKD trial later in the current quarter. The Chief Executive Officer confirmed the company's intention to submit an NDA for lorundrostat ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2025 Earnings Call Transcript May 12, 2025 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.79, expectations were $-1.02.

Investing.com -- Mineralys Therapeutics , Inc. (NASDAQ:MLYS) saw its stock jump 2.8% after reporting first quarter 2025 financial results that beat analyst expectations. The clinical-stage ...